Every patient advances lab-tracked care.
The Insights Program is a longitudinal data infrastructure that powers two things: your personalized data dashboard, and an aggregate dataset that drives protocol refinement. Every Mon Élan patient is enrolled by default. Opt out anytime.
Care is identical regardless of opt-status. No surveys. No engagement requirements. No participation gating. Data flows from normal clinical care.
The same infrastructure, two lenses.
Your personal data view, plus a research-grade aggregate dataset — built on the same clinical record, governed by different rules.
Your personalized dashboard
Every Mon Élan patient — regardless of opt-status — sees their own longitudinal lab trends, protocol responses, biomarker trajectories, and outcome measures surfaced in a personalized data dashboard. Your data, in your hands, with plain-language interpretation aligned to your treatment.
This output uses identifiable data within your own medical record under the HIPAA Treatment exception. It is not affected by opt-status.
Aggregate research dataset
De-identified per HHS Safe Harbor (45 CFR 164.514(b)), data from non-opted-out patients flows into an aggregate dataset that drives protocol refinement, identifies cohort-level patterns, and surfaces early-warning biomarker combinations that predict non-response or adverse effects.
This is what opt-out controls. Your clinical care is unaffected by opt-status.
Why opt-out, not opt-in.
The HIPAA Privacy Rule does not require opt-in for de-identified secondary data use. Most telehealth platforms that frame data participation as opt-in do so for marketing reasons, not legal ones — and the friction means most patients never participate.
We chose universal opt-out architecture because it preserves the data infrastructure value at scale while giving every patient explicit control. You're enrolled by default, you can opt out at intake or any time after, and your care is identical regardless. The opt-out election is captured as a discrete consent element separate from treatment consent.
What we will never do.
Four commitments we will not violate, regardless of what is technically permitted under HIPAA. These guarantees are part of our public clinical commitments and govern every operational decision.
Data sale for marketing or advertising
We do not sell your protected health information to marketing or advertising networks, and we do not use clinical data to target ads. Per HIPAA, any sale of PHI requires your written authorization, which we will not solicit. Our aggregate de-identified dataset is used internally to refine clinical protocols.
Differential care
Clinicians do not see your opt-status during patient encounters. Prescribing decisions, scheduling, response time SLAs, and care quality are unaffected.
Re-identification attempts
We do not attempt to re-identify aggregate data. Safe Harbor de-identification is permanent for the aggregate dataset.
Marketing without consent
We do not use your clinical data for marketing or product upsells. Marketing communications are based only on tier and explicit preferences you set.
Your assessment is eight minutes.
Insights Program enrollment is presented as a discrete consent element at intake — opt out then, or anytime after.
Begin assessment